The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-class PD-1/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC).
 
Jianya Zhou
No Relationships to Disclose
 
Xueli Bai
No Relationships to Disclose
 
Yiwen Chen
No Relationships to Disclose
 
Tingbo Liang
No Relationships to Disclose
 
Hui Wang
No Relationships to Disclose
 
Yuping Sun
No Relationships to Disclose
 
Xinjun Liang
No Relationships to Disclose
 
Qian Chu
No Relationships to Disclose
 
Lin Wu
No Relationships to Disclose
 
Caicun Zhou
Honoraria - Anheart Therapeutics; Hengrui Therapeutics; Merck Sharpe and Dohme; MSD; Sanofi; TopAlliance BioSciences Inc
Consulting or Advisory Role - Hengrui Therapeutics; Top Alliance BioScience
 
Jian Fang
No Relationships to Disclose
 
Yueyin Pan
No Relationships to Disclose
 
Jiuwei Cui
No Relationships to Disclose
 
Zhangzhou Huang
No Relationships to Disclose
 
Yu Chen
No Relationships to Disclose
 
Chengzhi Zhou
No Relationships to Disclose
 
Xiaoqing Liu
No Relationships to Disclose
 
Yu Yang
No Relationships to Disclose
 
Ning Li
No Relationships to Disclose
 
Tongmei Zhang
No Relationships to Disclose